Journal
REPRODUCTIVE SCIENCES
Volume 21, Issue 2, Pages 260-268Publisher
SAGE PUBLICATIONS INC
DOI: 10.1177/1933719113493514
Keywords
progesterone; preterm delivery; progesterone receptor; inflammation
Categories
Funding
- NIH [5T32GM008600-17]
- Society of Obstetric Anesthesia and Perinatology/Gertie Marx Research Grant
Ask authors/readers for more resources
Progesterone (P4) and the progestin, 17-hydroxyprogesterone caproate, are clinically used to prevent preterm births (PTBs); however, their mechanism of action remains unclear. Cytokine-induced matrix metalloproteinase 9 (MMP-9) activity plays a key role in preterm premature rupture of the membranes and PTB. We demonstrated that the primary chorion cells and the HTR8/SVneo cells (cytotrophoblast cell line) do not express the classical progesterone receptor (PGR) but instead a novel progesterone receptor, progesterone receptor membrane component 1 (PGRMC1), whose role remains unclear. Using HTR8/SVneo cells in culture, we further demonstrated that 6 hours pretreatment with medroxyprogesterone acetate (MPA) and dexamethasone (Dex) but not P4 or 17-hydroxyprogesterone hexanoate significantly attenuated tumor necrosis factor -induced MMP-9 activity after a 24-hour incubation period. The inhibitory effect of MPA, but not Dex, was attenuated when PGRMC1 expression was successfully reduced by PGRMC1 small interfering RNA. Our findings highlight a possible novel role of PGRMC1 in mediating the effects of MPA and in modulating cytokine-induced MMP-9 activity in cytotrophoblast cells in vitro.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available